Kala Bio Q2 net loss narrows to $1.58 million from year-ago $11.16 million

• Kala Bio posted a quarterly net loss of $1.58 million, narrowing from $11.16 million a year earlier.
• Total operating expenses fell to $1.72 million from $11.03 million, led by R&D dropping to $59,000 from $6.23 million.
• General and administrative expense declined to $1.66 million from $4.64 million, reflecting lower employee-related and stock-based compensation costs.
• Interest expense was nil versus $1.08 million, with no indebtedness outstanding under the Oxford Finance loan agreement.
• Shift toward an on-premises AI platform-as-a-service model continues, with development centered on the licensed Researgency agentic AI platform.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kala Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-098783), on August 19, 2026, and is solely responsible for the information contained therein.